India, March 5 -- CStone Pharmaceuticals (CSPHF.OB) Wednesday has applied for a Phase Ib clinical trial in Australia to test CS5001, a cancer drug, in combination with standard treatments for DLBCL. The drug is also being studied alone and with a PD-L1 inhibitor for solid tumors.
The trial will explore CS5001 in first-line and relapsed DLBCL, as well as solid tumors. CEO Dr. Jason Yang sees strong potential for the drug, citing promising past results.
The study is enrolling patients in the U.S., Australia, and China, with plans to expand into a larger Phase II trial soon.
CSPHF.OB is currently trading at $3.7 or 3.641% higher on the HKSE.
For comments and feedback contact: editorial@rttnews.com
Published by HT Digital Content Services ...